The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
CStone Pharmaceuticals' shares have risen after academic journal Nature Cancer published the clinical study results of its lung-cancer treatment sugemalimab.
Research has reinforced the efficacy of Lumakras (sotorasib), a small molecule inhibitor in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
There is an urgent need for more targeted treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although first-line treatment has shown potential in a clinical study.
Scientists have demonstrated that a tumour suppressor gene could
actually stimulate tumour progression, which if confirmed, could
raise possibilities of using the gene as a novel prognostic
indicator of tumour aggressiveness.
US scientists think they have come up with a novel test that
indicates how a patient with early-stage lung cancer will respond
to chemotherapy, giving the opportunity to tailor treatment to the
individual.
Pharmaceutical company, Phosphagenics, has announced the
commencement of animal studies on its anti-cancer compound, which
claims to destroy diseased cells while not affecting normal ones by
primarily acting as a signalling molecule...
A small molecule drug, which has been developed to treat solid
tumour and haematological cancer, has entered an Investigational
New Drug (IND) application that represents the emergence of aurora
kinase inhibitors as a viable cancer...
A group of researchers in the US have enhanced the abilities of
molecules they are creating to deliver medication to cancer cells.
The man-made molecular complexes enter cancer cells and, when
signalled, deliver killing medicine or...
Exelixis has submitted an investigational new drug application
(IND) to the US Food and Drug Administration (FDA) for XL820, a
novel small molecule anticancer compound that inhibits receptor
tyrosine kinases (RTKs) implicated in tumour...
The wealth of new targets identified from genomics and the
discoveries made in the molecular pathology of cancer will give
rise to a new generation of cancer treatment, moving one step
closer to individualised, target therapy.
Cyclacel has received a US patent that covers a novel series of
pyrimidine small molecules shown to inhibit the progress of cells
through the cancer cell cycle. The patented compounds may be useful
as therapeutics for cancer, inflammatory...
Hana Biosciences announced today the clinical trial initiation of
PT-523 to evaluate this compound as a single agent in relapsed
non-small cell lung cancer (NSCLC). Lung cancer continues to carry
the poorest prognosis of cancer,...
German contract manufacturer Strathmann Biotec has won a contract
to manufacture clinical supplies a new type of cancer treatment in
development at Sweden's Active Biotech.
